Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer

Clinical Breast Cancer

Volumn 7, Issue 11, 2007, Pages 857-860

  Rossi, David ^a   Alessandroni, Paolo ^a   Catalano, Vincenzo ^a   Giordani, Paolo ^a   Fedeli, Stephano Luzi ^a   Fedeli, Anna ^a   Baldelli, Anna Maria ^a   Casadei, Virginia ^a   Ceccolini, Monica ^a   Catalano, Giuseppina ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Capecitabine; Cyclophosphamide; Methotrexate; Palmar plantar erythrodysesthesia

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SOFT TISSUE METASTASIS; STOMATITIS; UNSPECIFIED SIDE EFFECT; VISCERAL METASTASIS; VOMITING;

EID: 38049035076     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.050     Document Type: Article

References (11)

1. O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247-54.
2. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536-42.
3. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane pretreated breast cancer. Cancer 2001; 92:1759-68.
4. El-Helw L, Coleman R. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. Breast 2005; 14:368-74.
5. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 10:2155-61.
6. Miller AB, Hoogstraten B, Staquet H, et al. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
7. Gairard B, Matheson C, Scheffer P, et al. Breast cancer: epidemiology, risk factors, screening. Rev Pract 1998; 48:21-7.
8. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1998. Eur J Cancer 1997; 33:1075-107.
9. Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999; 26:1-10.
10. Leonard RC, Twelves C, Breddy J, et al. Capecitabine named-patient programme for patients with advanced breast cancer. The UK experience. Eur J Cancer 2002; 38:2020-4.
11. Stockler M, Sorjina T, Grimison P, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007; 25(18 suppl):39s (Abstract 1031).